Literature DB >> 7042903

Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics.

H W Smith, M B Huggins.   

Abstract

Anti-K 1 phages were more active in vitro and in vivo against an 018:K1:H7 ColV+ Escherichia coli strain, designated MW, than were other phages. A single intramuscular dose of one anti-K1 phage was more effective than multiple intramuscular does of tetracycline, ampicillin, chloramphenicol, or trimethoprim plus sulphafurazole in curing mice of a potentially lethal intramuscularly or intracerebrally induced infection of MW; it was at least as effective as multiple intramuscular doses of streptomycin. When MW and the phage were inoculated into different gastrocnemius muscles of the same mice, a rapid reduction in numbers of MW organisms occurred in the MW-inoculated muscle and in other tissues; the numbers of phage particles in the MW-inoculated muscle increased rapidly and greatly. MW failed to proliferate in the brains of intracerebrally infected mice that had been inoculated intramuscularly with the phage at the same time; many more phage particles were found in the brains of these mice than in other sites. The few phage-resistant mutants of MW found in the phage-treated mich were K1-; previous studies had shown such mutants to be of greatly reduced virulence. The phage administered intramuscularly 3-5 d before challenge with a potentially lethal intramuscularly induced infection of MW was protective, the protective effect varying between phage propagated on different bacterial strains.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042903     DOI: 10.1099/00221287-128-2-307

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  116 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Authors:  Alex R Hall; Daniel De Vos; Ville-Petri Friman; Jean-Paul Pirnay; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-01       Impact factor: 4.792

3.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 4.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments.

Authors:  A Vieira; Y J Silva; A Cunha; N C M Gomes; H-W Ackermann; A Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-10       Impact factor: 3.267

6.  Experimental evolution and bacterial resistance: (co)evolutionary costs and trade-offs as opportunities in phage therapy research.

Authors:  Pauline D Scanlan; Angus Buckling; Alex R Hall
Journal:  Bacteriophage       Date:  2015-05-21

7.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Reviving Phage Therapy for the Treatment of Cholera.

Authors:  Sudhakar Bhandare; Joan Colom; Abiyad Baig; Jenny M Ritchie; Habib Bukhari; Muhammad A Shah; Banwarilal L Sarkar; Jingliang Su; Brendan Wren; Paul Barrow; Robert J Atterbury
Journal:  J Infect Dis       Date:  2019-02-15       Impact factor: 5.226

9.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

10.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.